The current trading session has seen a notable upswing of 52.29% in the shares of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), currently valued at $3.43. This surge in LIXT stock is ascribed to the acclaim received by the company’s lead drug candidate.
Lixte Biotechnology (LIXT) has disclosed the publication of preclinical data in the digital pages of Cancer Discovery. The disseminated findings underscore the capability of LIXT’s leading clinical compound, LB-100, to coerce cancerous cells into relinquishing their carcinogenic properties, as delineated in the paper titled “Paradoxical activation of oncogenic signaling as a cancer treatment strategy.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
This revelation introduces a potential novel treatment avenue, supplementing LIXTE’s ongoing trio of clinical trials. As elucidated in the forthcoming July 2024 issue and concurrently released online, LB-100 has exhibited the capacity to induce a hyper-activation of signaling mechanisms responsible for the aberrant proliferation of cancer cells—a departure from conventional cancer therapies.
The orchestrated hyper-stimulation of cancer signals, when combined with a WEE1 kinase inhibitor, has demonstrated remarkable efficacy in eradicating colon cancer cells both in animal models and in vitro cultures. Notably, therapy resistance constitutes a primary cause of mortality in cancer cases.
Remarkably, resistance to LB-100 treatment appears to correlate with a reduction in the malignancy of cancer cells. Specifically observed in colon cancer cells, resistance to LB-100 led to a loss of key cancerous features, rendering the cells incapable of tumor formation in experimental animal models—a phenomenon termed “tumor suppressive drug resistance,” unique to LB-100.
The team of scientists behind these groundbreaking discoveries, led by Professor René Bernards at the Netherlands Cancer Institute and Oncode Institute in Amsterdam, comprises luminaries in the realm of molecular carcinogenesis. Professor Bernards, who also serves on the Board of Directors of LIXTE, spearheads this endeavor.
The distinctive impact of LB-100 on cancer cells lies in its coercion of cancer cells towards less malignancy as the sole recourse for survival—a concept that will be subject to clinical evaluation, distinct from the ongoing exploration of LB-100’s synergistic potential with checkpoint immunotherapy and chemotherapy in the three existing clinical trials.
